human TNFSF10 protein

dulanermin is the recombinant protein; DATR is a recombinant soluble mutant; RefSeq NM_003810

Also Known As:

TNFSF10 protein, human; Apo-2L protein, human; DATR protein, human; TRAIL protein, human; circularly permuted TRAIL protein, human; dulanermin; tumor necrosis factor (ligand) superfamily, member 10 protein, human

Networked: 19 relevant articles (5 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ashkenazi, Avi: 6 articles (04/2015 - 03/2010)
2.	Kapp, Amy V: 2 articles (04/2015 - 12/2013)
3.	Holland, Pamela M: 2 articles (05/2013 - 04/2010)
4.	Hsu, Cheng-Pang: 2 articles (10/2012 - 03/2010)
5.	Amler, Lukas: 2 articles (11/2011 - 03/2010)
6.	Blackhall, Fiona: 2 articles (11/2011 - 03/2010)
7.	Soria, Jean-Charles: 2 articles (11/2011 - 03/2010)
8.	Bai, Chunxue: 1 article (01/2018)
9.	Bai, Yuxian: 1 article (01/2018)
10.	Chen, Feng: 1 article (01/2018)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2018 - "The purpose of this study was to evaluate the efficacy and safety of dulanermin combined with vinorelbine and cisplatin (NP) as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). " 03/01/2010 - "In vitro sensitivity to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist antibody) is strongly predicted by the expression of the O-glycosylation enzymes GALNT14 in non-small cell lung cancer (NSCLC) cell lines (among others) and of FUT3/6 in colorectal cancer (CRC) cell lines. " 11/20/2011 - "To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC). " 11/20/2011 - "Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer." 03/20/2010 - "Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer."
2.	Colorectal Neoplasms (Colorectal Cancer) 12/01/2013 - "The study objectives were to evaluate the safety, tolerability, and preliminary efficacy of multiple doses of dulanermin in combination with modified FOLFOX6 and bevacizumab in previously untreated patients with locally advanced, recurrent, or metastatic colorectal cancer. " 12/01/2013 - "A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer." 12/01/2013 - "Overall, the addition of dulanermin to first-line FOLFOX plus bevacizumab was well tolerated in patients with advanced colorectal cancer, with similar AEs that would be expected from FOLFOX plus bevacizumab. " 03/01/2010 - "In vitro sensitivity to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist antibody) is strongly predicted by the expression of the O-glycosylation enzymes GALNT14 in non-small cell lung cancer (NSCLC) cell lines (among others) and of FUT3/6 in colorectal cancer (CRC) cell lines. "
3.	Osteosarcoma (Osteogenic Sarcoma) 09/01/2017 - "This study assessed the anticancer efficacy of evofosfamide in combination with the Proapoptotic Receptor Agonists (PARAs) dulanermin and drozitumab against human osteosarcoma in vitro and in an intratibial murine model of osteosarcoma. " 09/01/2017 - "These results suggest that evofosfamide may be an attractive therapeutic agent, with strong anticancer activity alone or in combination with either drozitumab or dulanermin against osteosarcoma." 09/01/2017 - "Under hypoxic conditions in vitro, evofosfamide cooperated with dulanermin and drozitumab, resulting in the potentiation of cytotoxicity to osteosarcoma cells. "
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/01/2015 - "We aimed to assess the safety, pharmacokinetics, and efficacy of dulanermin and rituximab in patients with relapsed indolent B-cell non-Hodgkin lymphoma. " 04/01/2015 - "The addition of dulanermin to rituximab in patients with indolent B-cell non-Hodgkin lymphoma was tolerable but did not lead to increased objective responses. "
5.	Neoplasms (Cancer) 01/01/2013 - "We use py-substitution to study the relationship between steady state and sensitivity to the anti-cancer drug candidate, dulanermin (recombinant human TRAIL). " 08/29/2022 - "Recently, APN inhibition has been shown to augment DR4-induced tumor cell death and thus overcome resistance to cancer treatment with DR4-ligand TRAIL, which is available as a recombinant soluble form dulanermin. " 08/01/2013 - "The patient had a rapid tumor relapse with metastatic disease to the liver and lung, and was enrolled in a phase 1b open-label clinical study, where he received the FOLFIRI regimen in combination with the pro-apoptotic receptor agonist dulanermin (rhApo2L/TRAIL). " 05/28/2013 - "In pre-clinical studies dulanermin demonstrates broad spectrum anti-tumor activity and the ability to cooperate with multiple conventional and targeted therapies. " 06/01/2012 - "Dulanermin in cancer therapy: still much to do."

Related Drugs and Biologics

1.	Bevacizumab (Avastin)
2.	Paclitaxel (Taxol)
3.	Carboplatin (JM8)
4.	drozitumab
5.	Cisplatin (Platino)
6.	Vinorelbine (Navelbine)
7.	Rituximab (Mabthera)
8.	TH 302
9.	Ligands
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)